Comparative Pharmacology
Head-to-head clinical analysis: BAL versus CUVRIOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAL versus CUVRIOR.
BAL vs CUVRIOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chelating agent that forms stable complexes with heavy metals (e.g., arsenic, mercury, lead) by binding to their sulfhydryl groups, facilitating renal excretion.
CUVRIOR (trientine) is a copper-chelating agent that forms stable complexes with copper, enhancing its excretion in urine. It also reduces intestinal absorption of copper.
3-5 mg/kg IM every 4 hours for 2 days, then every 6 hours for 1 day, then every 12 hours for 10 days.
300 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 6.8 hours (range 4–13 hours). In patients with impaired renal function, half-life may be prolonged.
Clinical Note
moderateBalsalazide + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Acetyldigitoxin
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Balsalazide."
Clinical Note
moderateBalsalazide + Ouabain
Terminal elimination half-life is approximately 0.9–1.5 hours; however, pharmacodynamic effects (copper mobilization) persist for 24–48 hours.
Primarily renal; approximately 80% of a dose is excreted in urine as unchanged drug and metabolites within 24 hours. Biliary/fecal elimination accounts for less than 5%.
Primarily hepatobiliary; unchanged drug and metabolites excreted in feces. Renal elimination accounts for <5% of the administered dose.
Category C
Category C
Chelating Agent
Chelating Agent
"The serum concentration of Ouabain can be decreased when it is combined with Balsalazide."